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beyond First Line
Ivana Sullivan and David Planchard*
Department Medical Oncology, Gustave Roussy, Villejuif, France
Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor 
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant 
non-small-cell lung cancer (NSCLC). First-generation EGFR TKIs, binding competitively 
and reversibly to the ATP-binding site of the EGFR tyrosine kinase domain, have 
resulted in a significant improvement in outcome for NSCLC patients with activating 
EGFR mutations (L858R and Del19). However, after a median duration of response of 
~12 months, all patients develop tumor resistance, and in over half of these patients this is 
due to the emergence of the EGFR T790M resistance mutation. The second-generation 
EGFR/HER TKIs were developed to treat resistant disease, targeting not only T790M 
but EGFR-activating mutations and wild-type EGFR. Although they exhibited promising 
anti-T790M activity in the laboratory, their clinical activity among T790M+ NSCLC was 
poor mainly because of dose-limiting toxicity due to simultaneous inhibition of wild-type 
EGFR. The third-generation EGFR TKIs selectively and irreversibly target EGFR T790M 
and activating EGFR mutations, showing promising efficacy in NSCLC resistant to the 
first- and second-generation EGFR TKIs. They also appear to have lower incidences 
of toxicity due to the limited inhibitory effect on wild-type EGFR. Currently, the first-
generation gefitinib and erlotinib and second-generation afatinib have been approved 
for first-line treatment of metastatic NSCLC with activating EGFR mutations. Among the 
third-generation EGFR TKIs, osimertinib is today the only drug approved by the Food 
and Drug Administration and the European Medicines Agency to treat metastatic EGFR 
T790M NSCLC patients who have progressed on or after EGFR TKI therapy. In this 
review, we summarize the available post-progression therapies including third-generation 
EGFR inhibitors and combination treatment strategies for treating patients with NSCLC 
harboring EGFR mutations and address the known mechanisms of resistance.
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iNTRODUCTiON
Over the past decade, scientific advances have progressively improved outcomes for patients diagnosed 
with lung cancers driven by target oncogene mutations. The first oncogenic driver in non-small-cell 
lung cancer (NSCLC) was discovered in 2004 with the identification of activating mutations in 
the kinase domain of the epidermal growth factor receptor (EGFR) among patients with dramatic 
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responses to EGFR tyrosine kinase inhibitors (TKIs) (1–3). EGFR 
mutations account for 10–17% of NSCLC cases in North America 
and Europe and 30–50% of NSCLCs in Asian countries and are 
most common among patients with adenocarcinoma NSCLC 
and a light or non-smoking history (4, 5). The first-generation 
TKIs gefitinib (Iressa®, AstraZeneca, London, UK) and erlotinib 
(Tarceva®, F. Hoffmann-La Roche, Basel, Switzerland), and the 
second-generation TKI afatinib (Giotrif®, Boehringer Ingelheim, 
Ingelheim, Germany) have shown higher response rates (RRs), 
improving progression-free survival (PFS) and quality of life 
compared to standard platinum-based chemotherapy in patients 
with good performance status (0–2) whose tumors harbor an 
activating (sensitizing) EGFR mutation (6–13).
These data established EGFR TKIs as the treatment of choice for 
patients with newly diagnosed EGFR-mutant advanced NSCLC. 
Of note, none of these studies demonstrated a benefit in terms of 
overall survival (OS) due to the high level of crossover. However, 
an unplanned pooled OS analysis of patients included in the 
LUX-Lung 3 or LUX-Lung 6 phase III trials demonstrated an OS 
benefit for afatinib compared to platinum-based chemotherapy in 
patients whose tumors harbor EGFR Del19 mutations vs. EGFR 
L858R mutations: 27.3 vs. 24.3 months, respectively [hazard ratio 
(HR) 0.81; 95% confidence interval (CI), 0.66–0.99; p = 0.037] 
(14). However, this benefit was not confirmed in the phase IIb 
LUX-Lung 7 designed to compare head-to-head afatinib with 
gefitinib in the first-line treatment of patients with EGFR-mutant 
NSCLC (15). Unfortunately, the majority of patients progress 
after a median of 12 months treatment with first-line TKIs, and 
multiple mechanisms of acquired resistance have been identified. 
Among them, the most common mechanism (~50% of cases) is 
the acquisition of a missense mutation within exon 20 of EGFR, 
the T790M mutation (p.Thr790Met) (16).
Until recently, standard chemotherapies were the main treat-
ment option in a post-progression setting. For patients initiating 
chemotherapy, the role of EGFR TKI maintenance remains 
controversial. In a retrospective analysis, up to 23% of patients 
experience a disease flare after TKI discontinuation (17), which 
led many clinicians to continue EGFR TKIs when starting chemo-
therapy. It was hypothesized that some clones within a resistant 
cancer remained sensitive to EGFR inhibition and that withdrawal 
of the TKI could “let loose” these clones with resultant adverse 
outcomes. The randomized phase III IMPRESS trial provided the 
first prospective data to address this clinical question. Patients 
progressing on first-line gefitinib were randomized to receive 
cisplatin–pemetrexed with gefitinib or placebo. The trial did not 
confirm a benefit of maintaining the EGFR TKI, with comparable 
RRs and PFS in the two arms (18). The final OS analysis was 
presented recently; patients in the gefitinib arm had significantly 
lower OS compared to the placebo arm (13.4 vs. 19.5  months, 
HR = 1.44, p = 0.016), confirming the deleterious effect of main-
taining the EGFR inhibition. Of note, this detrimental effect was 
predominantly observed among patients whose tumors harbored 
a T790M mutation detected via circulating tumor DNA (ctDNA; 
HR = 1.49; 95% CI, 1.02–2.21) (19).
To date, many third-generation EGFR TKIs have been devel-
oped to target both sensitizing EGFR mutations and EGFR T790M. 
In this review, we outline available post-progression therapies 
including osimertinib (previously known as AZD9291) as the 
only drug approved by the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) for the treat-
ment of patients with metastatic EGFR T790M+ NSCLC who 
have progressed on or after EGFR TKI therapy (20), and other 
next-generation irreversible EGFR TKIs in clinical development 
(Table 1).
iDeNTiFYiNG THe ACQUiReD 
ReSiSTANCe MeCHANiSM TO FiRST/
SeCOND-GeNeRATiON EGFR TKis
For patients whose disease progresses on gefitinib, erlotinib, or 
afatinib, understanding the major mechanisms of resistance is 
essential to choosing the optimal post-progression treatment. 
To date, repeated biopsies are the standard of care; however, 
this approach comes with some limitations—not all patients are 
amenable to this procedure, and not all progressing lesions are 
accessible for biopsy. In addition, there is growing evidence that 
a single biopsy may not accurately represent the intrinsic hetero-
geneity of a resistant tumor. Liquid biopsy is a valid alternative 
to tissue rebiopsy. This approach, which has been validated (21), 
represents a surrogate DNA source and is a novel strategy for 
tumor genotyping, mainly applicable at the time of progression 
for EGFR-mutated patients (22–24). In cases when the T790M 
mutation is identified in peripheral blood, treatment with third-
generation EGFR TKIs is justified (25).
In addition to T790M, other resistance mechanisms have 
also been identified. Globally, these can be categorized as target 
gene alterations (i.e., EGFR amplifications and mutations such as 
T790M), downstream bypass signaling pathway activation (i.e., 
MET and HER2 amplifications or mutations in BRAF, PIK3CA), 
and phenotypic changes (including small-cell lung cancer trans-
formation and epithelial to mesenchymal transition) (26, 27).
TARGeTiNG EGFR T790M+ NSCLC
Second-Generation EGFR TKis
Following the discovery that T790M is the main resistance 
mechanism against the first-generation EGFR TKIs gefitinib and 
erlotinib, many new drugs targeting T790M were developed. 
Although second-generation EGFR inhibitors such as neratinib, 
afatinib, and dacomitinib exhibited promising anti-T790M activ-
ity in the laboratory, their clinical activity in T790M+ NSCLC was 
poor, with RR less than 10% among patients resistant to gefitinib 
or erlotinib (28–30). In addition, increased toxicity, mainly skin 
and digestive (Table  1), was observed due to EGFR wild-type 
inhibition at lower concentrations than those required to inhibit 
T790M. Thus to date, none of the second-generation agents are 
considered as effective monotherapies in patients progressing on 
first-generation TKIs.
On the basis of preclinical observations that afatinib plus 
cetuximab (an anti-EGFR monoclonal antibody) overcame 
T790M-mediated resistance (31), this combination was evaluated 
in a phase Ib trial enrolling 126 heavily pretreated patients with 
advanced EGFR-mutant NSCLC who had developed resistance 
TAbLe 1 | EGFR TKi generations for metastatic EGFR-mutant NSCLC.
Generation 
TKi
Drug Company EGFR 
inhibition
Molecular targets Most common adverse events Status
First 
generation
Gefitinib AstraZeneca Competitive; 
reversible
EGFR L858R, Del19 Diarrhea, rash/acne, ALT/AST increased, 
decreased appetite
Phase III 
(approved)
Erlotinib F. Hoffmann-La 
Roche
Second 
generation
Afatinib Boehringer Ingelheim Covalent; 
irreversible
wt-EGFR, EGFR L858R, 
L858R/T790M, L858R/
T854A, wt-HER2, HER2 
amp., HER4
Skin rash, diarrhea Phase III 
(approved)
Dacomitinib Pfizer EGFR L858R, Del19, 
T790M, wt-HER2, mutant-
HER2, HER2 amp., HER4
Diarrhea, rash/acne Phase III
Neratinib Puma Biotechnology EGFR L858R, T790M, 
HER2, HER4
Diarrhea, dyspnea, nausea, vomiting Phase III
Third 
generation
Osimertinib AstraZeneca Covalent; 
irreversible
EGFR L858R, Del19, T790M 
(limited activity against 
wt-EGFR)
Diarrhea, rash, nausea, decreased appetite Phase III 
(approved)
Rociletinib Clovis Hyperglycemia, long QT interval, nausea, 
fatigue, diarrhea
Phase II/III 
(stopped)
Olmutinib Hanmi/Boehringer 
Ingelheim
Diarrhea, rash, skin exfoliation, nausea,  
pruritus
Approved in  
South Koreaa
ASP8273 Astellas Diarrhea, nausea, vomiting, platelet count 
decreased
Phase III
Nazartinib Novartis Rash, diarrhea, pruritus Phase I/II
PF-06747775 Pfizer No reported yet Phase I/II
Avitinib Ace Bio No reported yet Phase I
HS-10296 Jiangsu Hansoh No reported yet Phase I/II
aDue to an unexpected increase of grade 3/4 skin toxicity, the ELUXA clinical trial program was temporally stopped.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Del, deletion; amp, amplification; TKIs, tyrosine kinase inhibitors; wt, wild-type; EGFR, epidermal growth factor receptor.
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to erlotinib/gefitinib. The overall response rate (ORR) was 29% 
and was comparable in both T790M+ and T790M− tumors 
(32 vs. 25%), and median PFS was 4.7 months (95% CI, 4.3–6.4) 
(32). However, the dual EGFR inhibition resulted in increased 
toxicity with various grades 3–4 adverse events (AEs) (mainly 
rash, diarrhea, and fatigue) reported in up to 46% of patients (32). 
A randomized phase II/III trial (NCT02438722) of afatinib plus 
cetuximab vs. afatinib alone is currently open in treatment-naïve 
patients with advanced EGFR-mutant NSCLC.
Third-Generation EGFR TKis
Many third-generation EGFR inhibitors are currently being 
consecutively developed to more effectively target the T790M 
mutation. Unlike second-generation TKIs, as these drugs exhibit 
increased specificity for T790M and thus mutant EGFR compared 
to wild-type EGFR, they are well tolerated resulting in few wild-
type EGFR adverse effects. Among them, osimertinib (AZD9291) 
was the first to receive FDA and EMA approval in November 
2015 and February 2016, respectively, for metastatic EGFR 
T790M+ NSCLC, which has progressed on or after EGFR TKI 
therapy. Table 2 shows available efficacy data of new-generation 
EGFR TKIs.
Osimertinib (AZD9291; Tagrisso®)
Osimertinib is a mono-anilino-pyrimidine compound that acts 
as a covalent EGFR TKI. In EGFR recombinant enzyme assays, 
osimertinib showed potent activity against diverse EGFR muta-
tions (L858R, L858R/T790M, exon 19 deletion, and exon 19 
deletion/T790M) and exhibited nearly 200 times greater potency 
against L858R/T790M than wild-type EGFR. Osimertinib is 
metabolized to produce at least two circulating metabolites, 
AZ5104 and AZ7550. In biochemical assays, AZ7550 had a com-
parable potency and selectivity profile to osimertinib, although 
AZ5104 showed greater potency against exon 19 deletions, 
T790M mutants (both ~8-fold) and wild-type (~15-fold) EGFR 
(33). Its pharmacokinetic exposure did not significantly differ 
between Asian and non-Asian patients, showing a minimal food 
effect (34). Additionally, data from a clinical pharmacokinetic 
study (NCT02163733) showed that osimertinib exposure was not 
affected by concurrent administration of omeprazole (35). Thus, 
unlike first- and second-generation TKIs, gastric pH modifying 
agents can be concomitantly used with osimertinib without 
restrictions.
A phase I/II dose-escalation study of osimertinib (AURA, 
NCT01802632) was carried out in patients with locally advanced 
or metastatic EGFR-mutated NSCLC progressing on first- or 
second-generation EGFR TKIs. Patients were not preselected 
according to T790M status (36). The study included 253 patients 
who received osimertinib at five dose levels ranging from 20 
to 240  mg daily and distributed between two cohorts, dose-
escalation and dose-expansion cohorts. Among 31 patients 
enrolled in the dose-escalation cohort, no dose-limiting toxicity 
TAbLe 2 | efficacy of third-generation tyrosine kinase inhibitors (TKis) in activating epidermal growth factor receptor (EGFR) mutations and T790M+ 
NSCLC patients.
Osimertinib Rociletinib Olmutinib ASP8273 Nazartinib
Trial AURA phase I AURA phase I 
T790M+
AURA 
phase II 
ext.
AURA2 
phase II 
TIGER-X phase I/IIa HM-EMSI-101 
phase I/II  
T790M+ 
(ongoing)
NCT02113813  
phase I/II (ongoing)
NCT02108964 
phase I/II 
(ongoing)
T790M+
Pooled analysis
Patients (N) 253  
T790M+ = 138
63 201 210 69  
T790M+ = 51
76 63  
T790M+ = 58
152
Dose 20–240 mg qd 80 mg qd 80 mg qd 500, 625, or 750 mg bid 800 mg qd 300 mg qd 75–350 mg qd
ORR 
actEGFRm (%)
51 [95% CI, 45–58] – – 17 [95% CI, 4–41] – 30 –
ORR T790M+ 
(%)
61 [95% CI, 52–70] 71 [95% CI, 57–82] 66 [95% CI, 61–71] 45 (95% CI, 31–60) 62 29 (central testing) 46.9
Overall mPFS 
(95% CI) mo
T790M+: 9.6 (8.3–NR)
T790M−: 2.8 (2.1–4.3)
9.7 (8.3–13.6) 11.0 (9.6–12.4) T790M+: 6.1 (4.2–9.6)
T790M−: 1.8 (1.2–3.0)
6.9 (5.4–9.5)b T790M+: 6.8 (5.5–NR)c
T790M−: 6.0 (4.1–9.8)
9.7 (7.3–11.1)
Reference Jänne et al. (36) Yang et al. (37) Sequist et al. (41) Park et al. (44), 
Lee et al. (45)
Yu et al. (49) Tan et al. (51)
aUpdated results from 69 reviewed cases included in the phase I TIGER-X trial.
bUpdated results from 2016 ASCO Annual Meeting.
cmPFS from 28 NSCLC patients with central testing T790M+.
actEGFRm, activating EGFR mutation; bid, twice daily; CI, confidence interval; ext., extension; mo, months; mPFS, median progression-free survival; NR, not reached; ORR, overall 
response rate; qd, once daily.
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(DLT) occurred and the maximum tolerated dose (MTD) was 
not reached. An additional 222 patients were treated in five dose-
expansion cohorts. The EGFR-T790M mutation was detected in 
tumors from 138 patients (62%) in the expansion cohorts. Of 
the 253 patients treated across all dose levels, 239 were evaluated 
for response. The ORR and disease control rate (DCR) in the 
whole population were 51% [95% CI, 45–58%] and 84% [95% CI, 
79–88%], respectively. Among the 138 patients with a centrally 
confirmed EGFR-T790M mutation, 127 patients were evaluable 
for response. Outcomes were substantially better in the EGFR 
T790M+ population compared to T790M− tumor patients with 
an ORR of 61% [95% CI, 52–70%] vs. 21% [95% CI, 12–34%], 
a DCR of 95% [95% CI, 90–98%] vs. 61% [95% CI, 47–73%] 
and median PFS of 9.6  months [95% CI, 8.3–not reached] vs. 
2.8  months [95% CI, 2.1 to 4.3], respectively (36). There were 
no DLTs at any dose level. The most common AE, mostly grade 
1–2, were diarrhea (47%), skin toxicity (rash/acne, 40%), nausea 
(22%), and anorexia (21%). With increased incidence and severity 
of AEs (rash, dry skin, and diarrhea) in relation to the wild-type 
EGFR inhibition at higher dose levels (160 and 240 mg), 80 mg 
daily was selected as the recommended dose for further clinical 
trials (36).
The efficacy and safety data from the 80  mg expansion 
cohort in patients with centrally confirmed T790M NSCLC 
were recently updated (data cutoff: January 4, 2016). Among 
63 patients, 61 patients were evaluable for response. The ORR 
and DCR were 71% [95% CI, 57–82%] and 93% [95% CI, 
84–98%], respectively, with a median PFS of 9.7  months [95% 
CI, 8.3–13.6] (37).
The 80-mg daily dose evaluated in the phase II T790M+ exten-
sion cohort of the AURA trial (described above) was evaluated in 
an additional phase II “AURA2” study (NCT02094261) designed 
for patients with confirmed EGFR-mutant T790M+ locally 
advanced or metastatic NSCLC progressing on an approved 
EGFR TKI. A preplanned pooled analysis of both studies was 
performed. Among 411 patients (201 from the AURA exten-
sion and 210 from AURA2), 397 were evaluable. The ORR and 
DCR were 66% [95% CI, 61–71%] and 91% [95% CI, 88–94%], 
respectively. Median PFS was 11.0 [95% CI, 9.6–12.4] months 
with a median duration of response of 12.5  months [95% CI, 
11.1 months to not calculable] (37).
Osimertinib has also demonstrated activity in the first-line 
setting. Data from two expansion cohorts in treatment-naïve 
EGFR-mutated advanced NSCLC patients were recently pre-
sented. Sixty patients received osimertinib 80  mg (n =  30) or 
160 mg (n = 30) once daily and all were evaluable. The confirmed 
ORR was 77% [95% CI, 64–87%] with a DCR of 98% [95% CI, 
89–100%]. Median PFS was 19.3  months [95% CI, 13.7 to not 
calculable] (38).
A number of phase III trials involving osimertinib in different 
settings are ongoing. The phase III FLAURA trial (First-Line-
AURA; NCT02296125) in EGFR-mutated treatment-naïve 
NSCLC patients was designed to compare osimertinib 80  mg 
daily vs. the current standard of care gefitinib or erlotinib. The 
AURA3 trial (NCT02151981) is an open-label, randomized trial 
in the second-line setting, designed to compare osimertinib with 
platinum-based doublet chemotherapy in patients with EGFR 
T790M+ locally advanced or metastatic NSCLC. In a press 
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release dated July 18, 2016, AstraZeneca announced that the 
AURA3 trial, which included more than 400 patients, had met 
its primary endpoint demonstrating superior PFS compared to 
standard platinum-based chemotherapy.
In the adjuvant setting, the ongoing ADAURA trial (ADjuvant-
AURA; NCT02511106) is a double-blind, randomized, placebo-
controlled trial assessing the efficacy and safety of osimertinib 
vs. placebo in patients with EGFR-mutated stage IB–IIIA NSCLC 
following complete tumor resection. Results are not yet available.
Rociletinib (CO-1686)
Rociletinib is another oral, irreversible, mutant-selective inhibi-
tor of commonly mutated forms of EGFR, including T790M, 
with minimal activity against wild-type EGFR in preclinical 
studies (39). A phase I/II trial (TIGER-X; NCT01526928) of 
rociletinib was performed in patients with EGFR-mutant NSCLC 
with acquired resistance to first- or second-generation EGFR 
TKIs (40). In the expansion (phase II) part of the study, patients 
with T790M+ NSCLC received rociletinib at doses of 500, 625, 
or 750 mg twice daily. At the time of report, 130 patients were 
enrolled. The MTD was not identified. The most common grade 
3 AE was hyperglycemia, occurring in 20 of the 92 patients (22%) 
who received therapeutic doses. Among the 46 evaluable patients 
with T790M+, the ORR was 59% [95% CI, 45–73%]. For the 17 
evaluable patients with T790M− disease, the ORR was 29% [95% 
CI, 8–51%] (40).
In November 2015, Clovis Oncology issued a press release that 
contained data from a pooled analysis of TIGER-X and TIGER-2 
(NCT02147990), another phase II trial examining rociletinib in 
second line in patients with EGFR T790M+ NSCLC progress-
ing on at least on EGFR inhibitor. Among 325 patients, the 
ORR (dose range, 500–750 mg twice daily) was 30.2% [95% CI, 
25.2–35.5%]. The ORRs were 32% [95% CI, 25–40%] and 23% 
[95% CI, 14–34%] in patients receiving 625 mg (n = 170) and 
500 mg (n = 79), respectively. The median duration of response 
for the two treatment doses was 8.8 and 9.1 months, respectively. 
Due to the different RR, an independent updated analysis was 
assessed in patients (intention-to-treat population) included in 
the TIGER-X trial confirming ORRs of 45% [95% CI, 31–60%] 
and 17% [95% CI, 4–41%] among patients with T790M+ and 
T790M− disease, respectively (41). Clovis thus decided to halt 
enrollment in all ongoing rociletinib studies, including the phase 
III TIGER-3 trial (NCT02322281), and has withdrawn its applica-
tion for regulatory approval in the European Union.
Olmutinib (BI-1482694/HM61713; Olita™)
Olmutinib is an oral EGFR mutant-specific TKI active against 
mutant EGFR isoforms, including T790M, while sparing wild-type 
EGFR (42). A phase I/II trial HM-EMSI-101 (NCT01588145) was 
conducted to evaluate the safety, tolerability, pharmacokinetics, 
and preliminary activity of olmutinib in Korean patients with 
EGFR TKI-pretreated NSCLC (43). Patients received olmutinib 
at doses ranging from 75 to 1,200 mg/day. The ORR was 58.8% 
in the 34 patients who received olmutinib with a dose more 
than 650 mg. The most common DLTs involved gastrointestinal 
symptoms and increased aspartate aminotransferase, alanine 
aminotransferase, amylase, and lipase levels. The recommended 
phase II dose was 800 mg/day. In part II of the study, 76 patients 
with centrally confirmed T790M+ NSCLC were enrolled, 70 of 
whom were evaluable for response. The ORR was 61% and median 
PFS (n = 76) was 6.9 months [95% CI, 5.36–9.49]. The most com-
mon drug-related AEs (all grades) were diarrhea (59%), pruritus 
(42%), rash (41%), and nausea (39%) (44). These data validate 
previous preliminary trial results presented at the European 
Society for Medical Oncology Asia Congress in December 2015 
(45). These results were the basis for Breakthrough Therapy 
Designation granted by the FDA in 2015 and the first approval 
for the treatment of patients with EGFR T790M+ NSCLC in 
South Korea in 2016. Following promising early clinical data, 
Boehringer Ingelheim launched the ELUXA clinical trial pro-
gram to investigate olmutinib as a monotherapy in different set-
tings as well as in combination with other anticancer treatments. 
Nevertheless, due to an unexpected increase in grade 3/4 skin 
toxicity (epidermolysis) in previous trials Boehringer decided to 
definitively stop the development of this drug.
ASP8273
ASP8273 is another oral, irreversible TKI that inhibits the kinase 
activity of EGFR mutations including T790M, with limited activ-
ity against EGFR wild-type (46). ASP8273 was further shown to 
suppress signaling via ERK and Akt. This agent showed activ-
ity in mutant EGFR cell lines that are resistant to other EGFR 
TKIs including osimertinib and rociletinib (47). ASP8273 was 
evaluated in an open-label phase I/II study (NCT02192697) for 
safety and efficacy (48). Thirty Japanese patients were enrolled 
in the phase I dose-escalation cohorts across seven dose levels 
(25–600 mg/day), and 15 patients were enrolled in the response 
expansion cohorts across four dose levels (100–400  mg/day). 
T790M status was 49% positive, 13% negative, and 38% unknown, 
respectively. Responses were observed in patients enrolled in 
≥100  mg/day cohorts. Partial responses were achieved in 50% 
(18/36) of all evaluable patients and 80% (12/15) of patients with 
T790M+ NSCLC (including confirmed and unconfirmed). The 
most common AEs (all grades) were diarrhea (56%), nausea 
(31%), vomiting (31%), and thrombocytopenia (31%). Based on 
tolerability and preliminary antitumor activity, the recommended 
phase II dose selected was 300  mg once daily (48). The safety, 
tolerability, and antitumor activity for ASP8273 300 mg/day in 
patients with NSCLC EGFR mutation-positive and previously 
treated with an EGFR TKI were recently presented in a total of 63 
patients, including seven treated in the dose-escalation part, 18 in 
the response expansion, 19 in recommended phase II dose part, 
and 19 from the food effect cohort (49). The majority of tumors 
(>90%) were positive for the T790M mutation based on local 
testing. All but one patient (98%) had been previously treated 
with an EGFR TKI, with erlotinib the most common inhibitor. 
Among the 63 patients treated with ASP8273 300 mg, the ORR 
was 30% [95% CI, 19.2–43.0%] and the median PFS was 6.0 [95% 
CI, 4.1–9.8] months. For the subgroups with T790M+ tumors the 
ORRs, assessed by local or central testing, were similar: 31% [95% 
CI, 19.5–44.5%] and 29% [95% CI, 13.2–48.7%], respectively. 
Median PFS for T790M+ patients (local testing) was 6.0 months 
[95% CI, 5.3–9.8] and 6.8 months [95% CI, 5.5 months to not 
evaluable] for T790M+ patients (central testing). The most 
FiGURe 1 | Study design of nazartinib in EGFRm+ NSCLC patients (NCT0210896). EGFRm+, EGFR mutation-positive; MTD, maximum tolerated dose; qd, 
one daily; NSCLC, non-small-cell lung cancer; RP2D, recommended phase 2 dose.
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frequent drug-related AEs (all grades) were diarrhea (48%), 
nausea (27%), hyponatremia (19%), paresthesia (14%), and 
vomiting (13%). Six patients (10%) discontinued treatment due 
to treatment-related toxicity (49). Based on this study, the dose of 
ASP8273 300 mg daily was selected for a recently initiated, large 
(n = 600), international, randomized, phase III study (SOLAR) 
to compare the clinical efficacy and safety/tolerability of ASP8273 
with erlotinib or gefitinib as initial treatment of advanced EGFR-
mutant NSCLC (NCT02588261).
Nazartinib (EGF816)
Nazartinib is a novel, irreversible mutant-selective EGFR 
inhibitor that specifically targets both EGFR-activating muta-
tions (L858R, Del19) and the resistant T790M mutation, while 
sparing wild-type EGFR (50). NCT02108964 (EGF816X2101) 
is a phase I/II first-in-human study of nazartinib in patients 
with EGFR-mutated locally advanced or metastatic NSCLC. 
Updated results from the phase I dose-escalation part were 
recently presented. Patients were assigned to receive once-daily 
nazartinib with doses ranging from 75 to 350 mg. At the cutoff 
date of January 29, 2016, 152 patients had been treated across 
seven cohorts (51). Among them, 147 patients were evaluable for 
response. The confirmed ORR was 46.9% [95% CI, 38.7–55.3%] 
and the DCR was 87.1% [95% CI, 80.6–92.0%]. The estimated 
median PFS across all dose levels was 9.7  months [95% CI, 
7.3–11.1]. Among 69 patients with confirmed responses at the 
cutoff date, the estimated median duration of response was 
9.5  months [95% CI, 9.2–14.7]. The most common toxicities 
(all grades) were rash (54%), diarrhea (37%), and pruritus (34%). 
Interestingly, the rashes observed in the study tended to have a 
different pattern, location, and histology than those seen with 
other EGFR TKIs that target wild-type EGFR. Diarrhea was the 
most common grade 3/4 AE (16%), and of note, both incidence of 
diarrhea and rash tended to increase with increasing nazartinib 
doses (51). The phase II part, performed in six cohorts, is ongo-
ing (Figure  1). In addition, the drug is being investigated in 
association with INC280, a specific MET inhibitor (based on 
the potential escape pathway for third-generation EGFR TKIs) 
in an ongoing phase Ib/II trial in patients with advanced EGFR 
mutant NSCLC (NCT02335944), and with nivolumab, an anti-
PD-1 monoclonal antibody in a phase II trial in EGFR mutant/
T790M+ NSCLC patients who have progressed on first-line 
EGFR TKI (NCT02323126).
Avitinib (AC0010)
Avitinib is another new-generation inhibitor of EGFR that, like 
the abovementioned agents, targets EGFR-activating mutations 
overcoming T790M-induced mutation with limited activity 
against wild-type EGFR. Clinical trials were initiated in China 
and the United States in parallel using avitinib as second-line 
therapy in NSCLC patients progressing on first-generation EGFR 
TKIs and who have acquired the gatekeeper T790M mutation. 
Two trials evaluating the safety, tolerability, pharmacokinet-
ics, and antitumor activity of avitinib are ongoing; a phase I/II 
trial (NCT02274337) in advanced NSCLC patients progressing 
on prior therapy with an EGFR TKI agent and a phase I trial 
(NCT02330367) designed to determine the MTD and/or recom-
mended phase 2 dose in previously treated mutant EGFR NSCLC 
patients with a T790M resistant mutation.
PF-06747775
PF-06747775 is another small molecule inhibitor of EGFR T790M 
with minimal activity against wild-type EGFR. It is being studied 
in a phase I/II clinical trial (NCT02349633) in advanced NSCLC 
patients with EGFR mutations (Del19 or L858R  ±  T790M). 
Results are not yet available.
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HS-10296
HS-10296 is a small molecule inhibitor of EGFR-activating muta-
tions and T790M-resistant mutation with limited activity against 
wild-type EGFR. An open-label, multicenter, phase I/II trial of 
HS-10296 with dose escalation, dose expansion, and extension 
cohorts in locally advanced or metastatic NSCLC patients who 
have progressed following prior therapy with an EGFR TKI agent 
is currently recruiting participants (NCT02981108).
THiRD-GeNeRATiON EGFR TKis iN 
CeNTRAL NeRvOUS SYSTeM (CNS) 
MeTASTASeS
Incidence data of brain and leptomeningeal metastasis in 
EGFR-mutated NSCLC patients come from retrospective 
cohorts, reporting 24 and 9%, respectively. Gefitinib, erlotinib, 
and afatinib have impressive intracranial activity, with RR of 
60–80% (52, 53). However, for patients with CNS progression 
on these first- and second-generation agents, further effective 
therapies are limited. Among the third-generation EGFR TKIs, 
osimertinib was the only inhibitor demonstrating sustained 
tumor regression in both preclinical and clinical models (54). 
Osimertinib has greater penetration of the mouse blood–brain 
barrier than gefitinib, rociletinib, or afatinib, and induced sus-
tained tumor regression in an EGFR mutant PC9 mouse brain 
metastasis model at clinically relevant doses, while rociletinib did 
not achieve tumor regression (55). CNS activity was confirmed 
in the AURA study phase II extension cohort (NCT01802632) 
and the AURA2 phase II study (NCT02094261) (56). The 
phase I BLOOM trial (NCT02228369) was designed to assess 
for the first time the safety, tolerability, pharmacokinetics, and 
preliminary antitumor activity of two third-generation EGFR 
TKIs, orsimetinib and AZD3759. AZD3759 was the first EGFR 
TKI primarily designed to effectively across the blood–brain 
barrier to tackle CNS metastases in patients with EGFR mutant 
NSCLC (57, 58). The osimertinib cohort of the trial included 21 
Asian patients with advanced or metastatic NSCLC harboring 
the L858R mutation (n =  13) or an exon 19 deletion (n =  9), 
and a confirmed diagnosis of leptomeningeal metastasis by 
positive cerebrospinal fluid cytology. At study entry, the T790M 
mutation was detected in cerebrospinal fluid in two patients 
and in plasma in six. Patients received osimertinib at 160 mg/
day. All patients were evaluable for efficacy; seven (33%) had a 
confirmed radiologic response, nine (43%) had stable disease, 
and neurological function improvement was seen in five (24%) 
patients (59). Preliminary results from the AZD3759 cohort were 
recently presented (60). Twenty-nine patients with advanced 
EGFR mutant NSCLC and brain metastases, including lep-
tomeningeal metastasis were treated in escalating dose cohorts 
of 50–500 mg, twice daily (BID). The pharmacokinetic analysis 
demonstrated excellent CNS penetration, with a 1:1 ratio with 
plasma. The tolerability profile of AZD3759 was consistent with 
EGFR TKI class effects and included grade 3/4 rash (7%), pruri-
tus (7%), diarrhea (3%), and acne (3%). The MTD was 300 mg 
BID but study investigators recommended 200 mg BID for phase 
II dosing. AZD3759 demonstrated encouraging intracranial 
antitumor activity. Among 21 patients with measurable brain 
metastases, 11 demonstrated tumor shrinkage in the target brain 
lesion at AZD3759 doses of ≥50 mg BID. In this group, there 
were six partial responses (three confirmed, three unconfirmed). 
Among 22 patients with measurable extracranial lesions, eight 
experienced tumor shrinkage, with one unconfirmed partial 
response (60). Based on these promising findings, the BLOOM 
trial is continuing to enroll patients in the AZD3759 brain and 
leptomeningeal metastasis expansion cohorts.
MeCHANiSMS OF ReSiSTANCe TO 
THiRD-GeNeRATiON EGFR TKis
As is the case with first and second-generation EGFR TKIs, 
mutations mediating resistance to third-generation EGFR TKIs 
are emerging (61–65). Among them, while the C797S mutation in 
exon 20 of EGFR was the most common mechanism responsible 
for resistance to osimertinib (62), it occurs in less than 3% of 
patients treated with rociletinib (66). The C797S mutation was 
also reported in one case that led to resistance to olmutinib (65). 
Very recently, two novel tertiary EGFR mutations were described. 
The acquired L798I mutation was observed in cis with T790M 
in one patient following rociletinib therapy (66). Subsequently, 
another mutation in the same codon (L798Q) was reported in one 
patient at the time of progression under osimertinib (67).
The acquired resistance associated with the EGFR T790M muta-
tion can occur by selection of preexisting EGFR T790M+ clones 
or via genetic evolution of initially EGFR T790M− drug-tolerant 
cells, suggesting that cancer cells that survive third-generation 
TKIs may serve as a key reservoir from which acquired resistance 
can emerge during treatment (68).
Additional EGFR-independent mechanisms of resistance have 
been reported. NRAS mutations, including a novel E63K muta-
tion, and amplifications of wild-type NRAS or KRAS have been 
described as mechanisms of acquired resistance to osimertinib 
but also to gefitinib and afatinib (69). Amplifications in HER2 
and MET genes were also described as potential mechanisms 
of acquired resistance to osimertinib and rociletinib in EGFR 
T790M+ NSCLC patients (66, 70). Additionally, loss of T790M 
at the time of progression may be mediated by overgrowth of 
cells harboring HER2 amplification, or BRAF V600E or PIK3CA 
mutations, as was recently detected in plasma of patients included 
in the phase I AURA trial (71).
Finally, small-cell lung cancer transformation was seen in 
two cases of rociletinib resistance and one osimertinib-resistant 
patient; the T790M was lost while the original EGFR mutation 
was maintained in the small cell transformed cancer in each 
case (72, 73).
OveRCOMiNG ReSiSTANCe TO THiRD-
GeNeRATiON EGFR TKis
The favorable toxicity profiles of the third-generation EGFR 
TKIs make them particularly attractive candidates for combina-
tion therapy, and many trials are currently planned or ongoing 
(Table 3).
TAbLe 3 | Ongoing and forthcoming third-generation EGFR TKis-based combination trials.
Third-generation 
EGFR TKi
Trial, NCT 
number
Drug combination Mechanism of action Population and setting Primary endpoint Status
Osimertinib NCT02143466; 
TATTON  
Phase Ib
Durvalumab
Savolitinib
Selumetinib
Anti-PD-L1 antibody
MET inhibitor
MEK inhibitor
Advanced EGFR-mutant NSCLC progressing 
under EGFR TKI
Part A: safety and tolerability
Part B: safety, tolerability and efficacy
On hold
Recruiting
Recruiting
Osimertinib NCT02454933; 
CAURAL  
Phase III
Osimertinib monotherapy EGFR mutant/T790M+ NSCLC progressing 
under EGFR TKI
PFS On hold
Durvalumab Anti-PD-L1 antibody
Osimertinib NCT02496663; 
phase I
Necitumumab Anti-EGFR antibody Advanced EGFR-mutant NSCLC progressing 
under EGFR TKI
Safety and tolerability Recruiting
Osimertinib NCT02803203; 
phase I/II
Bevacizumab Anti-VEGF antibody Advanced EGFR-mutant NSCLC in the first-line 
setting
Phase I: MTD
Phase II: PFS
Recruiting
Osimertinib NCT02789345; 
phase I 
Necitumumab
Ramucirumab
Anti-EGFR antibody
Anti-vascular endothelial 
growth factor receptor 2 
antibody
EGFR mutant/T790M+ NSCLC progressing 
under first-line EGFR TKI
ORR Forthcoming
Necitumumab + ramucirumab
Osimertinib NCT02520778; 
phase Ib
Navitoclax Bcl-2 family inhibitor Advanced EGFR-mutant NSCLC progressing 
under EGFR TKI
Safety and tolerability Recruiting
Osimertinib NCT02503722; 
phase I/II
Sapanisertib TOR1/2 inhibitor Advanced EGFR-mutant NSCLC progressing 
under EGFR TKI
Safety and recommended phase II dose
Safety and efficacy in T790M− population
Recruiting
Nazartinib NCT02335944; 
phase Ib/II
INC280 MET inhibitor Ph. Ib/Ph. II Group 1: advanced EGFR-mutant 
NSCLC progressing under G/E/A
Ph. II Group 2: advanced NSCLC not been 
previously treated with any EGFR TKI and harbor 
de novo T790M mutation
Phase Ib: MTD or RP2D of nazartinib
Phase II: ORR
Recruiting
Nazartinib NCT02323126; 
phase II
Nivolumab Anti-PD-1 antibody EGFR mutant/T790M+ NSCLC progressing 
under first-line EGFR TKI
PFS On hold
G/E/A, gefitinib/erlotinib/afatinib; MTD, maximum tolerated dose; NCT number, http://clinicaltrials.gov identification number; NSCLC, non-small-cell lung cancer; ORR, objective response rate; PFS, progression-free survival; RP2D, 
recommended phase 2 dose.
8
S
ullivan and P
lanchard
Treating EG
FR
m
+
 N
S
C
LC
 beyond First Line
Frontiers in M
edicine | w
w
w
.frontiersin.org
January 2017 | Volum
e 3 | A
rticle 76
FiGURe 2 | Potential treatment algorithm for advanced EGFR-mutated NSCLC patients. CT, chemotheraphy; EGFR, epidermal growth factor receptor; 
MoR, mechanism of resistance; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer; TKI, tyrosine kinase inhibitor.
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Preclinical EGFR L858R/T790M/C797S mutation cell models 
exhibited in vitro sensitivity to cetuximab, an antibody that blocks 
EGFR dimerization (74, 75), but this was not confirmed in in vivo 
analyses. However, the allosteric inhibitor EAI045 in combination 
with cetuximab exhibited mechanistic synergy and was effective 
in mouse models of lung cancer driven by EGFR L858R/T790M 
and by EGFR L858R/T790M/C797S (76). Interestingly, the allelic 
context in which C797S was acquired may predict responsive-
ness to subsequent TKI treatments. For example, if the C797S 
and T790M mutations are in trans, cells will be resistant to third-
generation EGFR TKIs but are sensitive to a combination of first 
and third-generation TKIs, and when C797S develops in T790 
wild-type cells, this results in resistance to third-generation TKIs, 
while sensitivity to first-generation TKIs is retained (61). These 
data are of great clinical value in sequencing for this mutation in 
patients with acquired resistance to osimertinib.
Navitoclax (ABT-263), a BCL-2 family inhibitor, enhances 
the apoptotic response of late-resistant EGFR T790M cells with 
decreased sensitivity to EGFR inhibition. The combination of 
navitoclax with the third-generation EGFR TKI WZ4002 (in 
preclinical development) induced more apoptosis compared to 
WZ4002 alone in both in vivo and in vitro analyses. This approach 
could be an effective strategy for treating EGFR T790M-positive 
cancers that have a decreased apoptotic response to EGFR 
inhibition (68). Additionally, the combination of WZ4002 with 
trametinib, another MEK inhibitor, prevents the development of 
acquired resistance in EGFR-mutant lung cancer models (77). A 
phase Ib trial is ongoing to evaluate the safety and tolerability 
of the osimertinib/navitoclax combination in patients with 
EGFR-mutant NSCLC following resistance to prior EGFR TKIs 
(NCT02520778).
In vitro, a combination of osimertinib with the MEK 1/2 
inhibitor selumetinib prevented emergence of resistance in PC9 
(Ex19del) cells and delayed resistance in NCI-H1975 (L858R/
T790M) cells. In vivo, concomitant osimertinib with selu-
metinib caused regression of osimertinib-resistant tumors in an 
EGFR-mutant/T790M transgenic model (69). This association, 
among others, is being evaluated in the phase Ib TATTON trial 
(NCT02143466) designed to evaluate the safety, tolerability, and 
preliminary antitumor activity of osimertinib in combination 
with durvalumab (an anti-PD-L1 monoclonal antibody), savoli-
tinib (MET inhibitor) or selumetinib in patients with advanced 
EGFR-mutant NSCLC who have progressed on an EGFR TKI. 
Preliminary results from the osimertinib/durvalumab arm were 
recently presented (78). The investigator-assessed ORR was 67% 
in nine patients with T790M+ tumors, compared to 21% in 14 
T790M− NSCLC. Interstitial lung disease was reported in 38% 
(13/34) of patients, which is higher than would be expected with 
either drug alone, including five grade 3/4 events (78). Thus, 
recruitment in the osimertinib + durvalumab arm was stopped 
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but expansion cohorts of the MET and MEK inhibitor combi-
nations are ongoing. In addition, the phase III CAURAL trial 
(NCT02454933) is being conducted in second-line metastatic 
EGFR-mutant T790M+ NSCLC patients testing osimertinib plus 
durvalumab vs. osimertinib monotherapy. This study was also 
stopped prematurely due to the pulmonary toxicity observed in 
the TATTON trial.
Dual EGFR blockage is being evaluated in a phase I trial 
(NCT02496663) combining osimertinib with the anti-EGFR 
monoclonal antibody necitumumab to assess safety and deter-
mine the optimal dose in patients with EGFR-mutant advanced 
NSCLC who have progressed on a previous EGFR TKI.
As was reported, the dual vascular endothelial growth factor 
receptor (VEGFR) and EGFR blockade inhibit tumor growth in 
EGFR TKI resistance xenograft models (79). This hypothesis was 
confirmed in two phase II clinical trials in EGFR-mutant NSCLC 
treatment-naïve patients, the randomized Japanese (JO25567) 
trial comparing erlotinib plus bevacizumab vs. erlotinib alone, 
and the single-arm Caucasian (BELIEF) trial. Median PFS was 
similar and encouraging in both trials supporting the combination 
in the first-line setting (80, 81). Following this strategy, a phase I 
trial was designed to evaluate the safety of two osimertinib-based 
combination strategies, with necitumumab or ramucirumab (an 
anti-VEGFR2 monoclonal antibody) in patients with advanced 
EGFR T790M+ NSCLC after progression on first-line EGFR TKI 
therapy (NCT02789345). Finally, the osimertinib/bevacizumab 
combination will be evaluated in another phase I/II 3 + 3 dose-
escalation study (NCT02803203) to test the safety of combining 
these drugs.
For patients whose tumors undergo small-cell lung cancer 
transformation, platinum-based plus etoposide chemotherapy is 
recommended.
CONCLUSiON
Over the last decade, we have seen considerable advances in the 
treatment of patients with EGFR mutant NSCLC. Three EGFR 
TKIs are currently FDA and EMA approved for first-line treat-
ment of patients with sensitizing EGFR mutations in metastatic 
NSCLC. Despite this progress, the development of acquired 
resistance is an unfortunate reality and remains an important 
challenge in the clinical setting. No second-generation TKIs 
have been successfully developed, and to date, osimertinib is the 
only third-generation EGFR mutant/T790M+ TKI approved by 
the FDA and EMA for patients with advanced T790M NSCLC 
who progress on a first-line EGFR TKI. Osimertinib has 
demonstrated strong efficacy and safety data in phase I and II 
studies, mainly in a second- or post-second-line setting but also 
as first-line treatment, placing it as a very attractive drug in this 
scenario. The clinical development of osimertinib represents 
one of the fastest cancer drug development programs, taking 
just 2 years, 8 months, and 1 week from the first patient dosed 
to the first approved indication. Until recently, patients with 
advanced NSCLC with EGFR-activating mutations who pro-
gress on a first-line EGFR TKI have traditionally been treated 
with a platinum-doublet chemotherapy. These combinations 
show ORRs of approximately 30%, marginally higher than those 
observed in the T790M− populations, but significantly lower 
than those reported in T790M+ cohorts across osimertinib 
phase I–III trial development. In addition, given the encour-
aging CNS efficacy, osimertinib is also attractive as frontline 
treatment for patients with brain and/or leptomeningeal 
metastases. The phase III FLAURA (NCT02296125) trial will 
hopefully soon answer the issue of where osimertinib should be 
positioned. Among the other new-generation EGFR TKIs and 
considering that the development of rociletinib and olmutinib 
as monotherapies has been stopped, ASP8273 is now the most 
advanced agent in the clinic.
Figure  2 illustrates potential post-progression treatment 
algorithms for EGFR-mutated advanced NSCLC patients. The 
heterogeneity of resistant cancers seems to play an important 
role in both efficacy and resistance to these novel T790M-specific 
agents, and combination strategies could be effective in delaying 
and/or preventing resistance. Finally, in an era of personalized 
medicine, the analysis of both tumor tissue and ctDNA should be 
a priority to improve our knowledge to the benefit of our patients.
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